SynthesisBMC neurology2026
Patient-reported health utility in adults with myasthenia gravis: a systematic review and meta-analysis of EQ-5D outcomes.
Synthesis in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder associated with impaired health-related quality of life. EQ-5D utility and EQ-VAS scores are used in health economic evaluations, but reported estimates vary across MG populations, instruments, tariffs, and study designs.
methodsWe systematically searched PubMed, Embase, Scopus, and CENTRAL from inception to February 2026. Observational studies and randomized controlled trials reporting baseline or pre-intervention EQ-5D utility or EQ-VAS data in adults with MG were included. Random-effects meta-analyses used restricted maximum likelihood estimation. Subgroup, sensitivity, GRADE-informed certainty, and exploratory aggregate-level meta-regression analyses were performed.
resultsTen studies were included. Eight studies (n = 1,514) contributed to EQ-5D utility synthesis, yielding a descriptive pooled mean of 0.74 (95% CI 0.68-0.80), with very high heterogeneity (I² = 95.4%; Cochran Q p < 0.001) and a wide prediction interval (0.52-0.96). Seven studies (n = 2,760) contributed to EQ-VAS synthesis, with a descriptive pooled mean of 66.49 (95% CI 60.99-71.99), very high heterogeneity (I² = 96.3%; Cochran Q p < 0.001), and a wide prediction interval (47.70-85.28). Sensitivity analysis excluding the RCT baseline dataset did not materially change the pooled EQ-5D estimate. In an exploratory analysis based on two studies, utility declined across Myasthenia Gravis Foundation of America (MGFA) classes I-IV. Exploratory meta-regression suggested a possible negative association between mean disease duration and utility, but certainty was very low.
conclusionEQ-5D and EQ-VAS estimates indicate impaired patient-reported health status in MG, but pooled values should be interpreted as low-certainty descriptive summaries, not definitive utility inputs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.